Business Wire

DATAIKU

24.5.2023 11:01:30 CEST | Business Wire | Press release

Share
Dataiku Survey Reveals 84% of Companies Are Using Low- and No-Code Platforms to Achieve AI Goals

According to research run by Dataiku, the platform for Everyday AI, the power of data and AI is becoming increasingly available to non-technical employees at companies across EMEA.

The survey, which was run across the United Kingdom, France, the Netherlands, Germany, and the United Arab Emirates, polled over 700 senior decision makers of companies actively using data science platforms and AI models across the enterprise.

It identified a growing trend of empowered non-technical users working with data and AI to make pivotal business decisions. Forty seven percent of EMEA leaders indicated that their non-technical business users have full access to data and AI to attain business goals, and a further 49% stated that business users have at least some access. Eighty four percent of these companies across EMEA said that they are using low- and no-code platforms to achieve these AI goals.

Dataiku Senior Vice President and General Manager, Gregory Herbert, commented: “We’ve seen a great shift in accessibility via the use of low- and no-code platforms, but for many companies, there’s still extensive untapped potential when it comes to making data and AI available to non-technical business users. What we really want to see is AI that is so ingrained and intertwined with the workings of the day-to-day that it’s just part of the business — not only being used or developed by data scientists. If enterprises want to see a deeper transformation and truly data-driven business results, Everyday AI must become a reality for non-data-focused roles.”

AI Drives Momentum Despite Economic Volatility

The majority of companies (79%) surveyed across EMEA indicated they are leveraging AI to its full capacity, and more than 80% of firms indicated that they are able to measure the ROI of their AI investments.

The survey also indicated continued momentum with AI across EMEA. While leaders indicated that business acceleration (50%) and staying ahead of the competition (36%) were the initial top reasons for investing in AI, 2023 has seen a marked shift in AI business goals. When asked what the top three business goals companies were looking to achieve with AI over the next five years, innovation won out (59%), followed by cost reduction (49%) and increased revenue (48%.)

How Will the European Union’s New AI Regulation Impact Business?

The upcoming EU AI regulation requires that any business that commercialises an AI system as a service or a product on the European market conduct a risk assessment to identify risks for all AI systems across the enterprise. This includes any risk surrounding data quality, transparency, human oversight, and accountability.

While there have been criticisms of the EU AI Act’s potential impact on AI innovation, the survey revealed that nearly 80% of respondents did not feel it would hinder innovation and, rather, would introduce new opportunities.

-ENDS-

About Dataiku

Dataiku is the platform for Everyday AI that allows companies to leverage one central solution to design, deploy, govern, and manage AI and analytics applications. Since its founding in 2013, the company has been the leader in democratizing data and empowering organization-wide collaboration. Today, more than 500 companies worldwide use Dataiku to integrate and streamline their use of data, analytics, and AI, driving diverse use cases from fraud detection and customer churn prevention, to predictive maintenance and supply chain optimization. Stay connected with us on our blog, Twitter (@dataiku) and on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005027/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye